Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
249 questions in 68 reviews · Airways
current versionsNo studies 249 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Triple therapy vs LABA/LAMA combination Outcomes (weighted · people with stable COPD Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic… (2023) · Cochrane | no estimate extracted | NR | No studies |
Anxiolytics vs inactive control Cardiovascular mortality · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Anxiolytics vs inactive control Serious adverse events · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Anxiolytics vs inactive control Quality of sleep · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Anxiolytics vs inactive control Quality of life · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Anxiolytics vs inactive control All‐cause mortality · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Methylxanthine derivatives vs inactive control Cardiovascular mortality · adults with central sleep apnoea associated with heart failure in adults Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Methylxanthine derivatives vs inactive control Serious adverse events · adults with central sleep apnoea associated with heart failure in adults Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Methylxanthine derivatives vs inactive control Quality of sleep · adults with central sleep apnoea associated with heart failure in adults Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Methylxanthine derivatives vs inactive control Quality of life · adults with central sleep apnoea associated with heart failure in adults Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Methylxanthine derivatives vs inactive control All‐cause mortality · adults with central sleep apnoea associated with heart failure in adults Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypnotics vs inactive control Cardiovascular mortality · adults with primary central sleep apnoea Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypnotics vs inactive control Serious adverse events · adults with primary central sleep apnoea Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypnotics vs inactive control Quality of sleep · adults with primary central sleep apnoea Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypnotics vs inactive control Quality of life · adults with primary central sleep apnoea Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Hypnotics vs inactive control All‐cause mortality · adults with primary central sleep apnoea Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Carbonic anhydrase inhibitors vs inactive control Serious adverse events · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Carbonic anhydrase inhibitors vs inactive control Quality of sleep · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Carbonic anhydrase inhibitors vs inactive control Quality of life · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Carbonic anhydrase inhibitors vs inactive control All‐cause mortality · adults with central sleep apnoea associated with heart failure Pharmacological treatment for central sleep apnoea in adults (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA,… Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, MD‐ICS/LABA,… Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA,… Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, MD‐ICS/LAMA,… Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, MD‐ICS/LABA,… Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA,… Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of… (2023) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR MD‐ICS · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA,… Addition of long‐acting beta2 agonists or long‐acting muscarinic antagonists versus doubling the dose of… (2023) · Cochrane | no estimate extracted | NR | No studies |
Increased vs stable doses of inhaled corticosteroids Outcomes* · adults and children with chronic asthma Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Cardiovascular mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Serious adverse events Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Quality of sleep Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) All‐cause mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Time to life‐saving cardiovascular intervention Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Cardiovascular mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Serious adverse events Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Quality of sleep Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Quality of life Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation All‐cause mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Time to life‐saving cardiovascular intervention Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Cardiovascular mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Serious adverse events Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Quality of sleep Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Continuous positive airway pressure (CPAP) plus best supportive care vs best supportive care Serious adverse events Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) All‐cause mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs continuous positive airway pressure (CPAP) Time to life‐saving cardiovascular intervention Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Cardiovascular mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Serious adverse events Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Quality of sleep Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation Quality of life Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |
Adaptive servo ventilation (ASV) vs bilevel ventilation All‐cause mortality Non‐invasive positive pressure ventilation for central sleep apnoea in adults (2022) · Cochrane | no estimate extracted | NR | No studies |